ARCHIVES

Afinitor Increases Overall Survival To 3.5 Years in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

FOLFOX4 Improved PFS In Colorectal Cancer

April 25, 2008

DCT Board Okay Recompetitions, Delays Decision On Clonogenic Assays

June 24, 1983

How NCI Plans To Spend Funds In FY 1980

July 14, 1978

Three Geneticists Of “Knockout” Mice Fame Win Lasker Award For Basic Research.

September 28, 2001

DOD Seeks to Fund Innovative Research In 438 Million Prostate Cancer Program

August 22, 1997

Interferon “Hysteria” Prompts ASCO To Warn Against Expecting Immediate Benefits

June 20, 1980